GlassScriptPhysician profile
Sandip Jain
NPI 1750456869
$42,809.13
in general payments reported to CMS, 2019-2025
53 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,725 · 2020: $1,358 · 2021: $65.22 · 2022: $2,267 · 2023: $1,444 · 2024: $2,660 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,700 · Food and Beverage: $6,984 · Travel and Lodging: $2,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,850.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,700.00 |
| Food and Beverage | $6,983.91 |
| Travel and Lodging | $2,860.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21,684.58 | 2019-2025 | Uplizna |
| Argenx US, INC. | $9,943.64 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $1,807.06 | 2019-2025 | |
| Edw Pharma, INC. | $1,542.47 | 2019 | |
| Abbvie INC. | $826.00 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $630.57 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $629.35 | 2019-2025 | Mavenclad |
| Livanova USA, INC. | $603.28 | 2023-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $524.22 | 2023-2025 | Rystiggo, Briviact |
| Teva Pharmaceuticals USA, INC. | $464.70 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ptc Therapeutics, INC. | $336.73 | 2019 | |
| Tg Therapeutics, INC. | $307.02 | 2023-2025 | |
| Biogen, INC. | $278.40 | 2019-2025 | Vumerity, Tysabri |
| Acadia Pharmaceuticals INC | $236.09 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $216.75 | 2019-2025 | Ultomiris |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandip Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.